PeptideDB

BMS-604992 free base (EX-1314 free base) 760944-56-7

BMS-604992 free base (EX-1314 free base) 760944-56-7

CAS No.: 760944-56-7

BMS-604992 (EX-1314) free base is a selective, orally bioactive, small molecule growth hormone secretagogue receptor (GH
Sales Email:peptidedb@qq.com

This product is for research use only, not for human use. We do not sell to patients.

BMS-604992 (EX-1314) free base is a selective, orally bioactive, small molecule growth hormone secretagogue receptor (GHSR) agonist. BMS-604992 free base has high affinity (ki=2.3 nM) and strong functional activity (EC50=0.4 nM). BMS-604992 free base stimulates feeding in rodents.

Physicochemical Properties


Molecular Formula C24H31N7O5
Molecular Weight 497.54684472084
Exact Mass 497.239
CAS # 760944-56-7
Related CAS # BMS-604992;674343-47-6;BMS-604992 dihydrochloride;1469750-46-6
PubChem CID 24882668
Appearance Typically exists as solid at room temperature
LogP 3.584
Hydrogen Bond Donor Count 3
Hydrogen Bond Acceptor Count 8
Rotatable Bond Count 12
Heavy Atom Count 36
Complexity 761
Defined Atom Stereocenter Count 1
SMILES

O(CC1C=CC=CC=1)C[C@H](C1=NN=C2C=CC=C(COC(N(C)CC(N)=O)=O)N12)NC(C(C)(C)N)=O

InChi Key HXOYZOFSGAXBOH-GOSISDBHSA-N
InChi Code

InChI=1S/C24H31N7O5/c1-24(2,26)22(33)27-18(15-35-13-16-8-5-4-6-9-16)21-29-28-20-11-7-10-17(31(20)21)14-36-23(34)30(3)12-19(25)32/h4-11,18H,12-15,26H2,1-3H3,(H2,25,32)(H,27,33)/t18-/m1/s1
Chemical Name

[3-[(1S)-1-[(2-amino-2-methylpropanoyl)amino]-2-phenylmethoxyethyl]-[1,2,4]triazolo[4,3-a]pyridin-5-yl]methyl N-(2-amino-2-oxoethyl)-N-methylcarbamate
HS Tariff Code 2934.99.9001
Storage

Powder-20°C 3 years

4°C 2 years

In solvent -80°C 6 months

-20°C 1 month

Shipping Condition Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)

Biological Activity


Targets EC50: 0.4 nM (GHSR), Ki: 2.3 nM (GHSR)[1]
ln Vitro BMS-604992 demonstrates strong functional activity (EC50=0.4 nM) and high-affinity binding (Ki=2.3 nM) for the ghrelin receptor[1].
ln Vivo In comparison to mice given with vehicle, BMS-604992 (500 μg/kg; ip; 5 minutes) significantly increases stomach emptying[1]. With a minimum effective dose of roughly 10 mg/kg, BMS-604992 (1~1000 mg/kg; po; 1 hour) elicits a dose-responsive increase in food intake in comparison to vehicle-treated controls and exhibits a dose-linear increase in plasma concentrations at the 1-hour time point[1]. At the 5-minute mark, BMS-604992 (300 mg/kg; po; 5~20 minutes) significantly alters the situation[1]. Compared to vehicle-treated controls, BMS-604992 (500 μg/kg; ip; 4 hours) increases food intake by around two times[1].
Animal Protocol Animal/Disease Models: C57BL/6 mice
Doses: 500 μg/kg
Route of Administration: Ip; 5 minutes
Experimental Results: Resulted in a significant increase in gastric emptying compared with vehicle-treated mice.

Animal/Disease Models: C57BL/6 mice
Doses: 1~1000 mg/kg
Route of Administration: Po; 1 hour
Experimental Results: demonstrated a dose-linear increase in plasma concentrations at the 1 hour time point and elicited a dose-responsive increase in food intake relative to vehicle-treated controls, with a minimum effective dose of approximately 10 mg/kg.

Animal/Disease Models: SD rat
Doses: 300 mg/kg
Route of Administration: Po; 5~20 minutes
Experimental Results: Observed a significant difference at the 5 minutes time point.

Animal/Disease Models: Male GhrR KO and WT mice
Doses: 500 μg/kg
Route of Administration: Ip; 4 hrs (hours)
Experimental Results: Increased food intake approximately 2-fold compared with vehicle-treated controls.
References

[1]. Enhanced gastrointestinal motility with orally active ghrelin receptor agonists. J Pharmacol Exp Ther. 2009 Jun;329(3):1178-86.


Solubility Data


Solubility (In Vitro) May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
Solubility (In Vivo) Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.

Injection Formulations
(e.g. IP/IV/IM/SC)
Injection Formulation 1: DMSO : Tween 80: Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution 50 μL Tween 80 850 μL Saline)
*Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution.
Injection Formulation 2: DMSO : PEG300 :Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO 400 μLPEG300 50 μL Tween 80 450 μL Saline)
Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO 900 μL Corn oil)
Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals).
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO 900 μL (20% SBE-β-CD in saline)]
*Preparation of 20% SBE-β-CD in Saline (4°C,1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution.
Injection Formulation 5: 2-Hydroxypropyl-β-cyclodextrin : Saline = 50 : 50 (i.e. 500 μL 2-Hydroxypropyl-β-cyclodextrin 500 μL Saline)
Injection Formulation 6: DMSO : PEG300 : castor oil : Saline = 5 : 10 : 20 : 65 (i.e. 50 μL DMSO 100 μLPEG300 200 μL castor oil 650 μL Saline)
Injection Formulation 7: Ethanol : Cremophor : Saline = 10: 10 : 80 (i.e. 100 μL Ethanol 100 μL Cremophor 800 μL Saline)
Injection Formulation 8: Dissolve in Cremophor/Ethanol (50 : 50), then diluted by Saline
Injection Formulation 9: EtOH : Corn oil = 10 : 90 (i.e. 100 μL EtOH 900 μL Corn oil)
Injection Formulation 10: EtOH : PEG300:Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL EtOH 400 μLPEG300 50 μL Tween 80 450 μL Saline)

Oral Formulations Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium)
Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose
Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals).
Oral Formulation 3: Dissolved in PEG400
Oral Formulation 4: Suspend in 0.2% Carboxymethyl cellulose
Oral Formulation 5: Dissolve in 0.25% Tween 80 and 0.5% Carboxymethyl cellulose
Oral Formulation 6: Mixing with food powders

Note: Please be aware that the above formulations are for reference only. InvivoChem strongly recommends customers to read literature methods/protocols carefully before determining which formulation you should use for in vivo studies, as different compounds have different solubility properties and have to be formulated differently.

 (Please use freshly prepared in vivo formulations for optimal results.)
Preparing Stock Solutions 1 mg 5 mg 10 mg
1 mM 2.0098 mL 10.0492 mL 20.0985 mL
5 mM 0.4020 mL 2.0098 mL 4.0197 mL
10 mM 0.2010 mL 1.0049 mL 2.0098 mL
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.